Drugs

Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492

Photo from Vasileios Askoxylakis/LinkedIn

Apr 12, 2024, 11:49

Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492

Vasileios Askoxylakis, Vice President, Global Head Oncology Early Clinical Development at Servier, shared on LinkedIn:

“Very excited to see clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492 presented for the first time at AACR24. I had the honor and privilege to work with an amazing team and lead the IND and the first-in-human clinical trial of JBH492 during my tenure as Clinical Program Leader at Novartis Institutes for Biomedical Research. Congratulations to my colleagues and friends at Novartis!”

Source: Vasileios Askoxylakis/LinkedIn

AACR24 cancer CCR7 targeting antibody-drug clinical data Clinical Program Leader first-in-human clinical trial JBH492 Novartis Novartis Institutes for Biomedical Research OncoDaily Oncology Vasileios Askoxylakis

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage